Some reasons it probably won't:
1) Physiologically, prognostically, histologically: patients w/ severe COVID-19 resemble recent ARDS cohorts, in whom 1-year lung fxn is nearly normal
2) When fibrosis is present post-ARDS, it's rarely progressive.
nejm.org/doi/full/10.10…
1/3
1) Physiologically, prognostically, histologically: patients w/ severe COVID-19 resemble recent ARDS cohorts, in whom 1-year lung fxn is nearly normal
2) When fibrosis is present post-ARDS, it's rarely progressive.
nejm.org/doi/full/10.10…
1/3
3) IL-6 levels are lower in COVID-19 than other causes of ARDS, despite the hype
4) Common risk factors = good argument for confounding, not causality
2/3
4) Common risk factors = good argument for confounding, not causality
2/3
It's fine to "be prepared" but let's wait for data before prioritizing study/tx of post-COVID fibrosis over far more certain post-ICU sequelae: functional deficits, cognitive decline, PTSD, readmissions, etc.
ncbi.nlm.nih.gov/pubmed?term=21…
3/3
ncbi.nlm.nih.gov/pubmed?term=21…
3/3
